Gujarat Kidney to acquire 51% of UAE's Blue Tree Clinics for Rs 19.84 crore

What Gujarat Kidney announced

On 9 July 2026, the Board of Directors of Gujarat Kidney and Super Speciality Ltd (BSE: 544666) approved the acquisition of a 51 % equity stake in Blue Tree Clinics LLC, a Dubai‑based polyclinic. The purchase price is Rs 19.84 crore, to be paid in two cash tranches, with the entire transaction expected to close within 50 days of signing the Share Purchase Agreement. In the same board meeting, the company also appointed Dr Paresh Dhoti (DIN 11802188) as an additional non‑executive independent director and resolved to call a postal ballot for a special resolution to vary the objects of its IPO.

Details of the acquisition

Target business and financial profile

Blue Tree Clinics LLC is a licensed polyclinic operating in Dubai, United Arab Emirates. Its service portfolio includes:

• Plastic surgery
• Laser cosmetic procedures
• General dental care
• Chiropractic services

The clinic reported gross revenue of AED 10,538,978 and a net profit of AED 3,138,809 for the fiscal year 2025. The company has a simple share structure with three shareholders: one holding 91.866 % and two others holding the remaining 8.114 %. No promoter or promoter‑group of Gujarat Kidney has any interest in the target, and the transaction is classified as non‑related‑party.

Consideration and payment terms

• Total consideration: Rs 19,83,64,500 (approximately Rs 19.84 crore)
• Payment mode: Cash
• Tranches: Two installments, with the exact schedule to be disclosed later
• Completion timeline: Maximum of 50 days from the date of agreement

The acquisition will give Gujarat Kidney 51 % voting control over Blue Tree Clinics, effectively making it the majority shareholder.

Rationale disclosed by the board

The board stated that the acquisition is aimed at expanding the company’s existing business into a new geography and adding a set of medical services that are outside the current Indian operations of Gujarat Kidney. By entering the UAE market, the company hopes to diversify its revenue base and leverage the established brand of Blue Tree Clinics in the Gulf region.

Board actions beyond the acquisition

• Additional director appointment: Dr Paresh Dhoti, a qualified medical professional, was appointed as an additional non‑executive independent director effective 9 July 2026.
• Postal ballot: The company will conduct a postal ballot to seek shareholder approval for a Special Resolution to vary the objects of its IPO. Details of the resolution will be filed separately.

"The Board has approved the acquisition of a majority stake in Blue Tree Clinics LLC and the appointment of an additional independent director, reflecting its strategic intent to broaden geographic reach and service offerings," – Board of Directors, Gujarat Kidney.

Key facts at a glance

Why this matters for investors

The acquisition represents geographic diversification for Gujarat Kidney, moving from a purely Indian footprint to the Gulf region, where medical tourism and high‑value cosmetic procedures are growing. Because the deal is funded entirely in cash, it will reduce the company’s cash reserves by roughly Rs 20 crore, but it does not dilute existing shareholders’ equity. The board’s statement that the transaction is not a related‑party deal and is being executed at arm’s length should allay concerns about preferential pricing.

From a regulatory perspective, the company must obtain shareholder approval for the variation in IPO objects, which could affect the scope of future capital raising activities. The appointment of an additional independent director may strengthen governance, especially as the firm expands internationally.

Investors should monitor the completion timeline (maximum 50 days) and any subsequent disclosures regarding the exact tranche dates, financing arrangements, and post‑acquisition integration plans. The financial performance of Blue Tree Clinics, reported in AED, will also need to be translated into INR for future reporting, potentially introducing currency‑risk considerations.

Conclusion

Gujarat Kidney and Super Speciality Ltd has secured board approval to acquire a controlling 51 % stake in Dubai‑based Blue Tree Clinics LLC for approximately Rs 19.84 crore, with cash payment in two tranches and an expected close within 50 days. The move expands the company’s geographic reach and service portfolio, while the board also strengthened its governance by adding Dr Paresh Dhoti as an independent director. Final shareholder approval for the IPO object variation and the completion of the cash payment remain pending.

---

FAQs

1. What is the purchase price for the 51 % stake in Blue Tree Clinics? The acquisition cost is Rs 19,83,64,500, payable in two cash tranches.

2. How long will the acquisition take to complete? The board indicated a maximum timeline of 50 days from signing the agreement to full payment.

3. Is the transaction considered a related‑party deal? No. The filing explicitly states that the acquisition does not fall within related‑party transactions and is being done at arm’s length.

4. What services does Blue Tree Clinics provide? The target operates a polyclinic offering plastic surgery, laser cosmetic procedures, general dental care, and chiropractic services.

5. Will existing shareholders face dilution? The acquisition is funded entirely by cash, so no new shares are issued and there is no dilution of existing equity.

6. What additional corporate actions were announced alongside the acquisition? The board appointed Dr Paresh Dhoti as an additional independent director and announced a postal ballot for a special resolution to vary the objects of the IPO.